What is new with Dalcetrapib? | Why it is Different from the Other CETP Inhibitors?

Sunday, March 9, 2025

11:15 AM – 11:23 AM ET

Speaker(s)

Jean-Claude Tardif, MD

Director of Research Center
Montreal Heart Institute
Montreal, Quebec, Canada

Disclosure(s): Boehringer Ingelheim Pharmaceutical, Inc.: Grant/Research Support (Ongoing); Ceapro: Grant/Research Support (Ongoing); DalCor Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Merck Pharmaceuticals: Grant/Research Support (Ongoing); Novartis Pharmaceuticals: Grant/Research Support (Ongoing); Pfizer,: Grant/Research Support (Ongoing); Verve Therapeutics: Grant/Research Support (Ongoing)

Disclosure(s):

Jean-Claude Tardif, MD: Boehringer Ingelheim Pharmaceutical, Inc.: Grant/Research Support (Ongoing); Ceapro: Grant/Research Support (Ongoing); DalCor Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Merck Pharmaceuticals: Grant/Research Support (Ongoing); Novartis Pharmaceuticals: Grant/Research Support (Ongoing); Pfizer,: Grant/Research Support (Ongoing); Verve Therapeutics: Grant/Research Support (Ongoing)